NCT05194735View on ClinicalTrials.gov

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Gynecologic CancerColorectal CancerPancreatic CancerNon-small Cell Lung CancerCholangiocarcinomaOvarian CancerEndometrial CancerOvarian CarcinomaOvary NeoplasmSquamous Cell Lung CancerAdenocarcinoma of LungAdenosquamous Cell Lung Cancer
Interventions
BIOLOGICAL

Neoantigen specific TCR-T cell drug product

"Phase I:~Ascending dose, single Infusion of TCR+ Cells~Phase II:~Single infusion at the RP2D"

BIOLOGICAL

Aldesleukin (IL-2)

To support growth and activation of TCR-T cell drug product

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY